SAN DIEGO, July 7, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, today announced that it will host a Key Opinion Leader breakfast focused on Dravet syndrome, including an overview of ZX008, the Company's investigational proprietary pediatric formulation of low-dose fenfluramine, which is designated as an orphan drug for the treatment of Dravet syndrome in both the U.S. and Europe. Dravet syndrome is a rare and catastrophic form of intractable epilepsy that begins in infancy. The event and live webcast will take place on Tuesday, July 14 from 8 am-9:30 am Eastern Time in New York City.
The meeting will feature keynote presentations by key opinion leaders, Lieven Lagae, M.D., Ph.D., Professor at the University of Leuven, Belgium (KUL), Head of the Paediatric Neurology Department of the KUL University Hospitals and Director of the Childhood Epilepsy Program at the KUL University Hospitals, and Joseph Sullivan, M.D., Associate Professor of Neurology and Pediatrics at the University of California - San Francisco (UCSF) and Director of the UCSF Pediatric Epilepsy Center. Members of the Zogenix executive management team will also provide an overview of the Company's operations and ongoing clinical development work with ZX008, for which Zogenix intends to initiate Phase 3 clinical studies during the fourth quarter of 2015. Drs. Lagae and Sullivan, as well as members of the Zogenix executive management team, will also be available for Q&A following the presentations.
This event is intended for institutional investors and sell-side analysts. To reserve a place, please contact Mac MacDonald at 212-915-2567 or via e-mail at email@example.com. A live webcast and subsequent replay of the event will be available at http://lifesci.rampard.com/20150714.
Lieven Lagae, M.D., Ph.D., is a Professor at the University of Leuven, Belgium (KUL). He serves as Head of the Paediatric Neurology Department and Director of the Childhood Epilepsy Program at the KUL University Hospitals. His primary focus is the relationship between childhood epilepsy and cognitive development. Dr. Lagae's current epilepsy research projects include event-related potential studies of prefrontal functions in childhood epilepsy, wireless and miniaturized EEG systems for the detection of seizures and brain stimulation and new anti-epileptic drugs for childhood epilepsy. He is currently President of the European Pediatric Neurology Society and an elected Board Member of the International Child Neurology Association.
Joseph Sullivan, M.D., is an Associate Professor of Neurology and Pediatrics at UCSF and Director of the UCSF Pediatric Epilepsy Center. His primary interests are Dravet syndrome, PCDH19 Female Clustering Epilepsy and evaluating children for epilepsy surgery. Dr. Sullivan's current research projects include the Epilepsy Genetics Initiative, the Early Onset Epilepsy Study and developing an expert consensus statement for the treatment of Dravet syndrome. He serves on the PERC Steering Committee, the Dravet Syndrome Association Medical Advisory Board and the PCDH19 Alliance Scientific Advisory Board.
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with CNS disorders who need innovative treatment alternatives to help them return to normal daily functioning.
For more information, visit www.zogenix.com.
Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "indicates," "will," "plans," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding the timing of the commencement of Phase 3 clinical studies for ZX008. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in Zogenix's business, including, without limitation: the inherent risks of clinical development of ZX008, and Zogenix's dependence on third parties in such development; other difficulties or delays relating to the development, testing, manufacturing and marketing of and obtaining regulatory approval for ZX008; and other risks detailed in Zogenix's prior press releases as well as in public periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
CONTACT: Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com
Media: Catherine O'Connor
Sr. Director, Corporate Communications, Zogenix
858.436.3374 | firstname.lastname@example.orgZogenix, Inc.